Bristol-Myers' Opdivo fails to meet goal of brain tumor study

Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet a main goal of a late-stage trial, testing it in patients with a type of tumor that affects the brain or spine. The drug, when used along with the current standard of care for glioblastoma multiforme, did not prevent the cancer from spreading when compared with the standard of care alone, Bristol-Myers said. Glioblastoma multiforme is the most aggressive type of primary malignant tumor of the central nervous system and the standard of care can include radiation and chemotherapy.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001651 seconds